Intellia Therapeutics(NTLA)
CAMBRIDGE, MA
Biotechnology9 H-1B visas (FY2023)Focus: Therapeutic gene editing (CRISPR)
Intellia Therapeutics is a life sciences company focused on Therapeutic gene editing (CRISPR).
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
Hereditary AngioedemaClinical Trials (1)
NCT06262399Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
N/ALong-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyClinical Trials (1)
NCT05697861Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
N/APhase 1
Clinical Trials (1)
NCT04601051Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
Phase 1Biological NTLA-3001
Lung DiseaseClinical Trials (1)
NCT06622668NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
Phase 1/2REGV131
Hemophilia BClinical Trials (1)
NCT06379789A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Phase 1/2Biological NTLA-2002
Hereditary AngioedemaClinical Trials (1)
NCT05120830NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Phase 1/2Arm 1: NTLA-5001
Acute Myeloid LeukemiaClinical Trials (1)
NCT05066165Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
Phase 1/2Phase 3
Clinical Trials (1)
NCT06128629MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Phase 3nexiguran ziclumeran
Neuromuscular DiseaseClinical Trials (1)
NCT06672237A Phase 3 Study of NTLA-2001 in ATTRv-PN
Phase 3NTLA-2002
Hereditary AngioedemaClinical Trials (1)
NCT06634420HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2022
Portfolio: 10 clinical trials
Top TAs: Cardiovascular, Neurology, Rare Diseases
H-1B (2023): 9 approvals
SEC Filings: 2 available
Therapeutic Area Focus
Marketed
Pipeline
Financials (FY2025)
Revenue
$36M30%
R&D Spend
$435M(1199%)4%
Net Income
-$481MCash
$227MVisa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
9
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub